|
| Press Releases |
|
 |
|
| Friday, March 12, 2021 |
|
|
Eisai: Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Friday, March 5, 2021 |
|
|
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease |
| Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta protofibril antibody lecanemab, will be presented at the 15th International Conference on Alzheimer's and Parkinson's Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021. more info >> |
|
| Thursday, March 4, 2021 |
|
|
Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya |
| Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. more info >> |
|
| Tuesday, March 2, 2021 |
|
|
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong |
| Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Monday, February 22, 2021 |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090 |
| Eisai Co., Ltd. announced that it has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor E7090, which is currently under development as an orally available novel anti-cancer agent. more info >> |
|
|
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy |
| Eisai Co., Ltd. announced today that it has received the 18th Corporate Philanthropy Award (FY 2020) of the Japan Philanthropic Association. The presentation ceremony was held on February 19, 2021 (Friday) at the GakushiKaikan (Chiyoda-ku, Tokyo). more info >> |
|
| Monday, February 15, 2021 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the first presentation of new investigational data from the pivotal Phase 3 CLEAR study (Study 307/KEYNOTE-581) in an oral presentation session (Abstract #269) at the virtual 2021 Genitourinary Cancers Symposium (ASCO GU) and simultaneously published in the New England Journal of Medicine. more info >> |
|
| Wednesday, February 3, 2021 |
|
|
Two Immigrants, One Unique Plan For A Biopharma |
| The American Dream is why the United States is considered the "land of opportunity," and why for centuries immigrants have flocked to our shores seeking their fortunes. Sanjeev Redkar, Ph.D., (India) and Guo-Liang Yu, Ph.D., (China) came to the U.S. in the 1980s. By anyone's reasonable measure, both have achieved the American Dream. However, their dream as scientists remained at arm's length. more info >> |
|
| Monday, February 1, 2021 |
|
|
Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea |
| Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide"). This is the first launch of Equfina in the Asian region excluding Japan. more info >> |
|
| Tuesday, January 26, 2021 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time |
| Eisai Co., Ltd. announced that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The India Market Entry Dilemma: What's Holding Manufacturers Back
Apr 4, 2025 22:08 HKT/SGT
|
|
|
3rd Future Cross Border Payments Summit, Dubai 2025: Trends Shaping the Future of Payments
Apr 4, 2025 21:15 HKT/SGT
|
|
|
CISO Indonesia 2025: Elevating Cybersecurity Strategies for a Resilient Digital Future
Apr 4, 2025 20:50 HKT/SGT
|
|
|
analytica Vietnam 2025 Opens Tomorrow: The Leading Laboratory Exhibition Returns to Vietnam
Apr 4, 2025 20:40 HKT/SGT
|
|
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer 
Apr 4, 2025 19:41 HKT/SGT
|
|
|
Kirin and Hitachi begin joint research on the creation of forest-based carbon credits
Apr 4, 2025 15:56 JST
|
|
|
Asiaray Achieves Net Profit Turnaround of RMB10.4 Million in 2024
Apr 4, 2025 14:39 HKT/SGT
|
|
|
Mitsubishi Corporation Announces Corporate Strategy 2027
Apr 4, 2025 9:04 JST
|
|
|
SMBC and Fujitsu partner towards creation of AI-powered data analytics business
Apr 3, 2025 22:10 JST
|
|
|
Connect Marketplace Hong Kong 2025 Concludes Successfully
Apr 3, 2025 18:29 HKT/SGT
|
|
|
JBM Healthcare Completes Acquisition of 90% Interest in Tin Hee Tong
Apr 3, 2025 17:30 HKT/SGT
|
|
|
Guinean Artist Elie Kamano to Release New Single Exploring Africa's Colonial Past
Apr 3, 2025 17:00 HKT/SGT
|
|
|
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025
Apr 3, 2025 17:00 HKT/SGT
|
|
|
JF SmartInvest Holdings Ltd Announces 2024 Annual Results
Apr 3, 2025 15:59 HKT/SGT
|
|
|
AEON CREDIT SERVICE (ASIA) COMPANY LIMITED FY2024/25 Revenue Up to HK$1,759.3 million with Net Profit of HK$400.5 million
Apr 3, 2025 14:04 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
